Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
nL-ATN1-002 for DRPLA
NCT07084311Phase 2Active, not recruiting
- Sponsor
- n-Lorem Foundation
- Start
- Oct 2024
- Primary completion
- Nov 2026
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nL-ATN1-002 in dentatorubral-pallidoluysian atrophy (DRPLA), sponsored by n-Lorem Foundation. Primary endpoint: Seizures at 24 months. Started Oct 2024; status: active, not recruiting.
02
Drugs
nL-ATN1-002
03
Conditions
dentatorubral-pallidoluysian atrophy (DRPLA)
Beyond the preview
Go deeper on NCT07084311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07084311.